Abstract

Magnesium sulfate (MgSO₄) is the agent most commonly used for treatment of eclampsia and prevention of eclampsia in patients with severe pre-eclampsia. Another commonly practiced off-label use of this drug is in preventing preterm labor in pregnant women where the duration of the treatment might be more than one week. It is usually given either by intramuscular or intravenous route. After administration, about 40% of plasma magnesium is bound with protein. The unbound magnesium ion diffuses into the extravascular extracellular space and then diffuses into bone. It also crosses the placenta and fetal membranes and then diffuses into the fetus and amniotic fluid. Magnesium is almost exclusively excreted in the urine; 90% of the dose is excreted during the first 24 hours after an intravenous infusion of MgSO₄. The clinical effect and toxicity of MgSO₄ can be linked to its concentration in plasma. A concentration of 1.8–3.0 mmol/L has been suggested for treatment of eclampsia. The actual magnesium dose and concentration needed for prophylaxis have never been estimated. Maternal toxicity is rare when MgSO₄ is carefully administered and monitored. Deep tendon reflexes, respiratory rate, urine output and serum concentrations are the most common variables for monitoring the toxic effect. Currently the United States (US) Food and Drug Administration (FDA) is advising health care professionals against using MgSO₄ injection for more than 5–7 days to stop preterm labor in pregnant women (off-label use). Administration of MgSO₄ injection to pregnant women for more than 5–7 days may lead to low calcium levels and bone problems in the fetus, including osteopenia and fractures. The harmful effect in the fetus with the shortest duration is not established. In light of this new safety information, the drug label for MgSO₄ injection, USP 50% has also been changed, including changing the pregnancy category to D from A and denoting the effect as “New teratogenic effects”. Similarly, the manufacturers of other MgSO₄ injection products have made similar changes to their drug labels. In this review, the currently available knowledge of the pharmacokinetics of MgSO₄ and its clinical usage for women with pre-eclampsia and eclampsia, its off-label use and safety concern regarding the warning announced by the FDA will be outlined.

Key words: Magnesium sulfate; Eclampsia; Pre-eclampsia; Preterm labor; Teratogenic effects

Introduction

Magnesium sulfate (MgSO₄) has been used in obstetrics for decades.³⁴ Although a variety of tocolytics are used in clinical practice, MgSO₄ remains one of the most commonly used tocolytic agents. This drug has been evaluated and used for its tocolytic properties for nearly 50 years.³⁵ It is approved to prevent seizures in pre-eclampsia (a condition in which the pregnant woman develops hypertension and proteinuria) and for control of seizures in eclampsia. Both pre-eclampsia and eclampsia are life-threatening complications that can occur during pregnancy. Pre-eclampsia can lead to eclampsia, seizures, stroke, multiple organ failure and

References

1. Professor, Department of Pharmacology & Therapeutics, Enam Medical College, Savar, Dhaka
2. Assistant Professor, Department of Pharmacology & Therapeutics, Gonoshasthya Samaj Vittik Medical College, Savar, Dhaka
death of the woman and/or baby. Many practitioners use long courses of MgSO₄, sometimes for months. MgSO₄ is usually given through a vein until contractions have slowed and the mother’s cervix has stopped thinning (effacing) or opening (dilating). Most recently, prevention of cerebral palsy in preterm infants has become another indication for administration of MgSO₄ to the mother.⁴,⁵

MgSO₄ is not a benign drug. It has been associated with significant adverse drug reactions, overdose (primarily from medication administration errors) and the potential for increased blood loss at delivery. Several minor side effects including feeling of warmth, flushing, nausea and vomiting, muscle weakness, somnolence, dizziness and irritation at the injection site may occur. Serious side effects are rare, but there may be loss of the patellar reflex (typically occurring at a serum concentration of 8–10 mEq/L) and respiratory depression (when serum magnesium level >13 mEq/L).⁶,⁷ Magnesium is used as a tocolytic and may increase the rates of cesarean delivery, and peripartum infection and/or hemorrhage. Neonatal depressive effects may also be of concern.⁸

**Physiological role of MgSO₄**

Several studies have reviewed the molecular and cellular physiology of magnesium in details in health and pregnancy.⁹-¹⁵ Magnesium, a divalent cation, is the fourth most common cation in the human body after sodium, potassium and calcium. It is the second most common intracellular cation after potassium. Intracellular magnesium is found predominantly in bone (53%) and in myocytes (27%)⁹ and is localized in the nucleus, microsomes, and mitochondria.¹⁰ Only 1% of total body magnesium is found extracellularly¹¹, with serum magnesium accounting for 0.3% of the total body magnesium content.⁹ Approximately 62% of serum magnesium circulates in ionized form.⁹ The normal serum magnesium level is 0.75–0.95 mmol/L (1.8–2.3 g/dL).¹⁰ Serum magnesium levels decline in pregnancy, likely due in part to hemodilution.¹³,¹⁴ In addition to serving as a cofactor for numerous reactions, including energy metabolism and nucleic acid synthesis, magnesium is implicated in regulation of adenylate cyclase, transmembrane ion flux, muscle contraction and neuronal activity, as well as controlling vasomotor tone, cardiac excitability and neurotransmitter release.¹⁴ MgSO₄ is known to reduce spontaneous and induced myometrial contractions.²,¹⁶ Magnesium is believed to effect contractility by competing with calcium in the sarcoplasmic reticulum, reducing the availability of calcium to participate in actin–myosin interaction and in myometrial repolarization. Magnesium is thought to act through both intra- and extracellular mechanisms resulting in decreased intracellular calcium availability by blocking channel-dependent influx of extracellular calcium and also by blocking agonist stimulated release of intracellular calcium via inositol 1,4,5-triphosphate receptor/channels.¹⁷,¹⁸ In vitro, MgSO₄ has been demonstrated to reduce spontaneous myometrial contractions at a concentration of 2–3 mmol/L (4–6 mEq/L), but suprapharmacologic level (8–16 mEq/L) is required to inhibit agonist-mediated cyclic uterine activity.¹⁷-¹⁹

**MgSO₄ therapy in pre-eclampsia**

Though the use of MgSO₄ is widespread and effective, its mechanism of action in pre-eclampsia remains unclear. Several possible mechanisms of action have been proposed. Its mechanism of action is likely multifactorial, encompassing both vascular and neurological mechanisms. Being a calcium antagonist, its effect on vascular smooth muscle to promote relaxation and vasodilatation may have a role in lowering total peripheral vascular resistance. In addition, MgSO₄ may have an effect on the cerebral endothelium to limit vasogenic edema by decreasing stress fiber contraction and paracellular permeability via calcium-dependent second messenger systems such as myosin light chain kinase. MgSO₄ may also act centrally to inhibit N-methyl-D-aspartate (NMDA) receptors, providing anticonvulsant activity by increasing the seizure threshold.⁶

**Pharmacology and clinical pharmacology of MgSO₄**

MgSO₄ has been evaluated and used for its tocolytic properties for nearly 50 years.²,³ Typically a 4–6 g loading dose over 15–30 minutes is followed by a continuous infusion of 2 g/hr, and this infusion may be increased up to 4–5 g/hr as needed in the absence of significant clinical side effects or oliguria. Dosage of MgSO₄ must be carefully adjusted according to individual requirement and response and administration of the drug should be discontinued as soon as the desired effect is obtained.

Both intravenous (IV) and intramuscular (IM) administrations are appropriate. IM administration of
the undiluted 50% solution results in therapeutic plasma levels in 60 minutes, whereas IV doses will provide a therapeutic level almost immediately. The rate of IV injection should generally not exceed 150 mg/minute (1.5 mL of a 10% concentration or its equivalent), except in severe eclampsia with seizures.

Solutions for IV infusion must be diluted to a concentration of 20% or less prior to administration. The diluents commonly used are 5% dextrose solution and 0.9% sodium chloride solution. Deep IM injection of the undiluted (50%) solution is appropriate for adults, but the solution should be diluted to a 20% or less concentration prior to such injection in children.

**MgSO4 in eclampsia**

In severe pre-eclampsia or eclampsia, the total initial dose is 10–14 g of MgSO4. Intravenously, a dose of 4–5 g in 250 mL of 5% dextrose solution or 0.9% sodium chloride solution may be infused. Simultaneously, IM doses of up to 10 g (5 g or 10 mL of the undiluted 50% solution in each buttock) are given. Alternatively, the initial IV dose of 4 g may be given by diluting the 50% solution to a 10 or 20% concentration; the diluted fluid (40 mL of a 10% solution or 20 mL of a 20% solution) may then be injected intravenously over a period of 3–4 minutes. Subsequently, 4–5 g (8–10 mL of 50% solution) is injected intramuscularly into alternate buttocks every four hours, depending on the continuing presence of the patellar reflex and adequate respiratory function. Alternatively, after the initial IV dose some clinicians administer 1–2 g/hr by constant IV infusion. Therapy should continue until paroxysms cease. A serum magnesium level of 6 mg/100 mL is considered optimal for control of seizures. A total daily (24 hour) dose of 30–40 g should not be exceeded. In the presence of severe renal insufficiency, the maximum dosage of MgSO4 is 20 gm/48 hrs and frequent serum magnesium concentrations must be obtained.

MgSO4 affects the central nervous system (brain and spinal cord) of the mother. If too much MgSO4 is given, the mother's reflexes will be slowed. Reflexes are usually checked about every 2–4 hours while the mother is on this medication.

It also affects the central nervous system of the fetus. If this medication has been given to the mother in large doses and the baby is born before the drug is cleared off from the mother's body, the baby may have temporary problems with breathing right after birth. These problems can be quickly reversed with medicine.

**Review of several studies regarding the effect of MgSO4 on mother and newborn**

Several studies have been carried out on pregnant women to observe the side effects of MgSO4 on the mother as well as on the newborn. The FDA identified 18 cases reported in FDA’s Adverse Event Reporting System describing skeletal abnormalities in neonates exposed to MgSO4 in-utero. MgSO4 was administered to mothers for tocolysis in pregnancy. The average duration of in-utero exposure to MgSO4 was 9.6 weeks (range 8–12 weeks) and the estimated average total maternal dose administered was 3,700 grams. The published case series describes neonates developing skeletal abnormalities related to osteopenia; some developed multiple fractures involving the ribs and long bones. The osteopenia and fractures were transient and resolved in cases when the outcome was reported. Based on these literature cases, it is plausible that bone abnormalities in neonates are associated with prolonged in-utero exposure to MgSO4. Osteopenia and fractures may result from hypermagnesemia, which in turn causes hypocalcemia in the developing fetus.

FDA also reviewed published epidemiologic studies. One of these studies found a statistically significant increase in bone abnormalities in neonates with in-utero exposure to MgSO4 for >7 days, compared to those exposed for <3 days. Another study found a significant difference at birth in the serum values of magnesium, calcium, phosphorus and osteocalcin (a marker of bone formation) between neonates unexposed to MgSO4 and those exposed in-utero to MgSO4 for more than 1 week; there was no difference in radius bone mineral content in the two groups. In these studies, the neonatal bone abnormalities described in association with in-utero MgSO4 exposure beyond 5–7 days included radiographic findings of radiolucent transverse metaphyseal bands of long bones such as the humerus. Most of the epidemiological studies reviewed were based on retrospective reviews of charts in individual hospitals; none of the reviewed studies involved large electronic health care databases. The long-term clinical significance of altered laboratory parameters and/or radiographic findings suggestive of bone abnormalities found in these studies is unclear because long-term follow-up data
are not available in many of these studies. In one study, 11 babies who had shown bone abnormalities at birth manifested no radiographic bone abnormality at 1 and 3 years of age.24

In the past, MgSO4 was thought safe for babies whose mothers were prescribed this drug. However, doctors are debating the significance of one 1997 study that challenges this view.32 In the University of Chicago a study was conducted in 1997 and found an increased number of neonatal deaths in women who were prescribed MgSO4 for preterm labor in comparison to those women who were given another preterm labor drug (ritodrine, terbutaline, indomethacin or nifedipine). A second group of women with advanced cervical dilation, but not eligible for preterm labor drugs received either a 4 gm dose of MgSO4 or a placebo (saline). The women who received MgSO4 dose or doses had a higher rate of neonatal deaths (8 deaths out of 75 pregnancies) than the control group (1 death out of 75 pregnancies). The difference was statistically significant.32 More studies are needed before definite conclusions can be made. In addition, because of the significant risk of developing eclampsia, the benefits of a woman being on MgSO4 may outweigh the risks to her and also to the baby.

A retrospective cohort study was carried out between January 2000 and February 2009 over 6654 women with pre-eclampsia who were treated with IV MgSO4 beginning with a 6 gm dose, followed by 2–3 gm/hr infusion. Total 88 (6%) infants were diagnosed with hypotonia. As maternal serum magnesium concentrations increased before birth, values of 1-minute and 5-minute Apgar scores became low and incidence of intubation in the delivery room, admission to special care nursery and hypotonia significantly increased.33

Another retrospective study was conducted from 1995 to 2003 in pregnant women who received tocolytic MgSO4. Cases (n=78) who received MgSO4 for >48 hrs were compared to controls (n=77) who received it ≤48 hrs for maternal side effects and neonatal outcome. The median neonatal magnesium level was significantly higher in cases 3.3 versus 2.6 mg/dL (p=0.016); however, neonatal mortality and morbidity rates were similar in both groups. Abnormal bone mineralization was encountered in 3 neonates (cases).22

More than 40 years ago, Lipsitz and English34 reported a case series of six infants who had hyporeflexia, hypotonia and respiratory depression which were attributed to MgSO4 given to the mother. Lipsitz later reported a larger case series including 37 infants in which he found a trend toward lower Apgar scores in association with maternal MgSO4 therapy.35 Stone and Pritchard36 were unable to confirm changes in Apgar scores in 118 infants born of women given MgSO4 for prevention of eclampsia. Donovan and colleagues37 reported decreased muscle tone in 20 newborn infants associated with maternal magnesium levels. Chesley38 found cord blood magnesium levels 70–96% of magnesium levels in the mother with a progressive increase in fetal levels as the duration of maternal MgSO4 therapy lengthened. Most of the literatures available till now have dealt with the information on the neonatal effects of MgSO4. In 2008, Rouse and colleagues4 randomized MgSO4 infusions or placebo in 2241 women delivered between 24 and 31 weeks gestation to find out the effects of MgSO4 on perinatal death and/or cerebral palsy at 2 years of age. MgSO4 therapy was not found to be associated with perinatal death, neonatal hypotonia or any other neonatal morbidities. However, such therapy was associated with a significant reduction in cerebral palsy, especially in infants born between 24 and 27 weeks gestation.

A systematic review was done on maternal and infant outcomes following MgSO4 therapy and addressed the issue of drug safety.39 This review included studies from both developed and developing countries. Findings indicated that the use of MgSO4 for pre-eclampsia reduced the risk of progression of the disease and found that the use of the drug among patients with eclampsia was associated with lower risks of maternal death, recurrent seizures and major morbidity. Other clinical reviews and toxicology studies also indicate that the drug is safe for indicated purposes in recommended dosages according to standardized protocol for administration and monitoring.40–42

Recent updates on prolonged use of MgSO4 issued by FDA

MgSO4 is approved to prevent seizures in pre-eclampsia and for control of seizures in eclampsia. Both pre-eclampsia and eclampsia are life-threatening complications that can occur during pregnancy. Pre-eclampsia can lead to eclampsia, seizures, stroke, multiple organ failure and death of the woman and/or
baby. FDA warns professionals against using MgSO₄ injection for more than 5–7 days to stop preterm labor in pregnant women. This use of the drug is off-label, which means that it is not an FDA-approved use of the drug. Administration of MgSO₄ injection in pregnant women longer than 5–7 days may lead to low calcium levels and bone problems in the developing baby or fetus, including thin bones called osteopenia and fractures. The shortest duration of treatment that can result in harm to the baby is not known. In light of this new safety information about low calcium levels and bone problems in the developing baby, the following information is added to the drug label for MgSO₄ injection, USP 50%. A new warning states that continuous administration of MgSO₄ injection beyond 5–7 days in pregnancy for the treatment of preterm labor can cause low calcium levels and bone changes in the baby. By changing the pregnancy category to D from A, a new teratogenic effects section conveys that there is potential harm to developing babies. This section also includes the concerns described under the new warning. Pregnancy category D means there is positive evidence of human fetal risk, but the potential benefits from using the drug in pregnant women may be acceptable in certain situations despite its risks. Pregnancy category A means that adequate and well controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy and there is no evidence of risk in later trimesters. A new Labor and Delivery section emphasizes that continuous administration of MgSO₄ injection to treat preterm labor is not FDA-approved, which means the safety and effectiveness of this use are not established.⁴³

**Conclusion**

Maternal mortality in the developing world is receiving increasing attention and it is a key emphasis of the millennium development goals (MDGs). The World Health Organization (WHO) reports that hemorrhage/bleeding, infections, unsafe abortions and eclampsia are common causes of maternal mortality, especially in developing countries. Severe pre-eclampsia and eclampsia-related deaths are common causes of preventable maternal deaths. Ninety nine percent of these deaths occur in low and middle income countries like Bangladesh. WHO has recommended the use of MgSO₄ as a safe and low-cost drug to manage severe pre-eclampsia and eclampsia. Studies have demonstrated that the drug significantly lowers the possibility of seizures in women with severe pre-eclampsia or eclampsia, prevents progression from severe pre-eclampsia to eclampsia and generally lowers maternal mortality. Furthermore, magnesium has been used as the standard drug for tocolysis during treatment of premature labor as off-label use and other drugs have been compared to it. Due to the warning issued by the FDA and also categorization of it as a teratogenic drug, the drug needs to be used cautiously and the risk assessment should be solely based on the benefits. Strict monitoring of drug scheduling and dose adjustment is highly recommended when it is absolutely indicated.

**References**

1. Magnesium sulfate use in obstetrics. Committee Opinion No. 573. American College of Obstetricians & Gynecologists. Obstet Gynecol 2013; 122: 727–728.
2. Hall DG, Mceaughey Jr, Corey EL, Thornton WN. The effects of magnesium therapy on the duration of labor. Am J Obstet Gynecol 1959; 78: 27–32.
3. Hutchison HT, Nichols MM, Kuhn CR, Vasicka A. Effects of magnesium sulphate on uterine contractility, intrauterine fetus, and infant. Am J Obstet Gynecol 1964; 88: 747–758.
4. Rouse DJ, Hirtz DG, Thom E, Varner MW, Spong CY, Mercer BM. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med 2008; 359: 895–905.
5. Magnesium sulfate before anticipated preterm birth for neuroprotection. Committee Opinion No. 455. American College of Obstetricians and Gynecologists Committee on Obstetric Practice; Society for Maternal-Fetal Medicine. Obstet Gynecol 2010; 115: 669–671.
6. Euser A, Cipolla M. Magnesium sulfate for the treatment of eclampsia: a brief review. Stroke 2009; 40: 1169–1175.
7. Hunter L, Givvins K. Magnesium sulfate: past, present, and future. J Midwif Womens Health 2011; 56: 566–573.
8. Rantonen T, Kaapa P, Gronlund J, Ekblad U, Helenius H, Kero P et al. Maternal magnesium sulfate treatment is associated with reduced brain-blood flow perfusion in preterm infants. Crit Care Med 2001; 29: 1460–1465.
9. Elin RJ. Magnesium: the fifth but forgotten electrolyte. Am J Clin Pathol 1994; 102: 616–622.
10. Wolfe FI, Torsello A, Fasanella S, Cittadini A. Cell physiology of magnesium. Mol Aspects Med 2003; 24: 11–26.
11. Standing committee on the scientific evaluation of dietary reference intakes, Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for calcium, phosphorous, magnesium, vitamin D, and fluoride. Washington, DC: National Academies Press, 1997: 190–249.
12. Kurzel RB. Serum magnesium levels in pregnancy and preterm labor. Am J Perinatol 1991; 8: 119–127.
13. Weissberg N, Schwartz G, Shemesh O, Brooks BA, Algur N, Eylath U. Serum and mononuclear cell potassium, magnesium, sodium and calcium in pregnancy and labour and their relation to uterine muscle contraction. Magnes Res 1992; 5: 173–177.
14. Fawcett WJ, Haxby EJ, Male DA. Magnesium: physiology and pharmacology. Br J Anesth 1999; 83: 302–320.
15. Quamme GA, Dirks JH. The physiology of renal magnesium handling. Ren Physiol 1986; 9: 257–269.
16. Kumar D, Zourlas PA, Barnes AC. In vitro and in vivo effects of magnesium sulfate on human uterine contractility. Am J Obstet Gynecol 1963; 86: 1036–1040.
17. Fomin VP, Gibbs SG, Vanam R, Morimiya A, Hurd WW. Effect of magnesium sulfate on contractile force and intracellular calcium concentration in pregnant human myometrium. Am J Obstet Gynecol 2006; 194: 1384–1390.
18. Phillippe M. Cellular mechanisms underlying magnesium sulfate inhibition of phasic myometrial contractions. Biochem Biophys Res Commun 1998; 252: 502–507.
19. Tica VI, Tica AA, Carlig V, Banica OS. Magnesium ion inhibits spontaneous and induced contractions of isolated uterine muscle. Gynecol Endocrinol 2007; 23: 368–372.
20. Yokoyama K, Takahashi N, Yada Y. Prolonged maternal magnesium administration and bone metabolism in neonates. Early Hum Dev. 2010; 86(3): 187–191.
21. Wedig KE, Kogan J, Schorry EK, Whitsett JA. Skeletal demineralization and fractures caused by fetal magnesium toxicity. J Perinatol. 2006; 26(6): 371–374.
22. Nassar AH, Sakhel K, Maarouf H, Naassan GR, Usta IM. Adverse maternal and neonatal outcome of prolonged course of magnesium sulfate tocolysis. Acta Obstet Gynecol Scan. 2006; 85(9): 1099–1103.
23. Malaeb SN, Rassi A, Haddad MC. Bone mineralization in newborns whose mothers received magnesium sulphate for tocolysis of premature labor. Pediatr Radiol. 2004; 34(5): 384–386.
24. Matsuda Y, Maeda Y, Ito M, Sakamoto H, Masaoka N, Takada M et al. Effect of magnesium sulfate treatment on neonatal bone abnormalities. Gynecol Obstet Invest 1997; 44(2): 82–88.
25. Schanler RJ, Smith LG, Burns PA. Effects of long-term maternal intravenous magnesium sulfate therapy on neonatal calcium metabolism and bone mineral content. Gynecol Obstet Invest 1997; 43(4): 236–241.
26. Santi MD, Henry GW, Douglas GL. Magnesium sulfate treatment of preterm labor as a cause of abnormal neonatal bone mineralization. J Pediatr Orthop 1994; 14(2): 249–253.
27. Holcomb WL, Shackelford GD, Petrie RH. Magnesium tocolysis and neonatal bone abnormalities: a controlled study. Obstet Gynecol 1991; 78(4): 611–614.
28. Cumming WA, Thomas VJ. Hypermagnesemia: a cause of abnormal metaphyses in the neonate. Am J Roentgenol 1989; 152(5): 1071–1072.
29. Lamm CL, Norton KL, Murphy RJ. Congenital rickets associated with magnesium sulfate infusion for tocolysis. J Pediatr 1988; 113(6): 1078–1082.
30. McGuinness GA, Weinstein MM, Cruikshank DP, Pitkin RM. Effects of magnesium sulfate treatment on perinatal calcium metabolism. II. Neonatal responses. Obstet Gynecol. 1980; 56(5): 595–600.
31. Riaz M, Porat R, Brodsky NL, Hurt H. The effects of maternal magnesium sulfate treatment on newborns: a prospective controlled study. J Perinatol 1998; 18(6 Pt 1): 449–454.
32. Kaplan W, Haymond MW, McKay S, Karaviti LP. Osteopenic effects of magnesium sulfate in multiple pregnancies. J Pediatric Endocrinology and Metabolism 2006; 19: 1225–1230.
33. Ghanavati MA, Alexander JM, McIntire DD, Savani RC, Leveno KJ. Neonatal effects of magnesium sulfate given to mother. Am J Perinatol 2012; 29: 795–800.
34. Lipsitz PJ, English IC. Hypermagnesemia in the newborn infant. Pediatrics 1967; 40: 856–862.
35. Lipsitz PJ. The clinical and biochemical effects of excess magnesium in the newborn. Pediatrics 1971; 47: 501–509.
36. Stone SR, Pritchard JA. Effect of maternally administered magnesium sulfate on the neonate. Obstet Gynecol 1970; 35: 574–577.
37. Donovan EF, Tsang RC, Steichen JJ, Strub RJ, Chen JW, Chen M. Neonatal hypermagnesemia: effect on parathyroid hormone and calcium homeostasis. J Pediatr 1980; 96: 305–310.
38. Chesley LC. Hypertensive disorders in pregnancy. J Midwif Womens Health 2011; 30(2): 99–104.

39. Macdonald SD, Lutsiv O, Dzaja N, Duley L. A systematic review of maternal and infant outcome following magnesium sulfate for pre-eclampsia/eclampsia in real world use. Int J Gynecol & Obstet 2012; 118(2): 90–96.

40. Alauddin M, Sarkar MK, Munshi S, Tapan N, Maitrayee SM. Efficacy and safety of magnesium sulphate (MgSO4) in the treatment of eclampsia. J Indian Med Assoc 2011; 109(7): 485–486.

41. Lu J, Nightingale CH. Magnesium sulfate in eclampsia and pre-eclampsia: pharmacokinetic principles. Clin Pharmacokinet 2000; 38(4): 305–314.

42. Ciarkowski SL, Stalburg CM. Medication safety in obstetrics and gynecology. Clinical Obstet Gynecol 2010; 53(3): 482–499.

43. FDA recommends against prolonged use of magnesium sulfate to stop pre-term labor due to bone changes in exposed babies. Safety announcement [5-30-2013]. Available at: http://www.fda.gov/drug safety/ucm353333.htm. Accessed May 2014.